Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020201097 - OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Publication Number WO/2020/201097
Publication Date 08.10.2020
International Application No. PCT/EP2020/058729
International Filing Date 27.03.2020
IPC
A61K 31/501 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/501
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • ASTRAZENECA AB [SE]/[SE]
Inventors
  • NASH, Anthony, Francis, Patrick
Agents
  • NESS, Mark, David
Priority Data
62/825,86729.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
(FR) OSIMERTINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES
Abstract
(EN)
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
(FR)
L'invention concerne des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique (EGFR) destinés à être utilisés dans le traitement de patients naïfs de TKI anti EGFR atteints d'un cancer du poumon non à petites cellules (CPNPC) positif à la mutation EGFR localement avancé ou métastatique, l'EGFR TKI étant administré en combinaison avec une chimiothérapie à base de platine-pémétrexed.
Latest bibliographic data on file with the International Bureau